{
  "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
  "created_date": "2023",
  "country": "FR",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "EVALUATION OF HEALTH TECHNOLOGIES",
      "text": "Sotorasib OPINION ON THE",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Adopted by the Commission on Transparency on 19 July 2023",
      "text": "Lung cancer - Adult - Sectors: City and Hospital Notice to maintain reimbursement \"in monotherapy in the treatment of adult patients with advanced non-small cell lung cancer (NCBC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line\" Place in LUMYKRAS (sotorasib) is an option for treatment in the management of adult patients with advanced rautical non-small cell lung cancer (NCBC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "(ISP)",
      "text": "Improvement No progress in relation to the medical service docetaxel rendered (ASMR) LUMYRAS (sotorasib) showed statistically significant superiority in terms of progression-free survival and objective response rate evaluated by an independent review committee in an open-label Phase 3 study compared to docetaxel. However, this result is limited by: - the lack of clinical relevance of the absolute difference in progression-free survival medians, about 1 month; - the open-label conduct of the study, resulting in pos-ible evaluation biases, particularly in terms of treatment decisions; - the uncertain reproducibility of progression-free survival measurement in this study;",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "cible",
      "text": "The Commission considers that LUMYKRAS (sotorasib) does not improve the medical service rendered (ASMR V) in relation to docetaxel.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "The target population is estimated at about 1950 patients.",
      "text": "S",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "Sommaire",
      "text": "Background Medical environment General of the disease or condition concerned Current management Coverage of the medical need Synthesis of the data Available data Synthesis of the efficacy data 3.2.1 Reminders of the clinical data previously reviewed by the Commission of 15/06/2022): CodeBreak study 100 (non-comparative basketball study) 3.2.2 New efficacy data provided in support of this re-evaluation: etu CodeBreak 200 Tolerance profile 3.3.1 Reminders of the clinical data previously examined by the Commission of 15/06/2022): CodeBreak study 100 (non-comparative basketball study) 3.3.2 New safety data provided in support of this re-evaluation Use data 3.4.1 Cohort UA 3.4.2 1st post-AMM early access report 3.4.3 Observational study IFCT-2102 Lung KG12Ci Study programme Discussion Commission's conclusions Place of the drug in the therapeutic strategy Clinically relevant comparators Medical Service Rendu Improvement of the Medical Service Rendu Target population Request for data Other recommendations of the",
      "start_page": 3,
      "end_page": 5
    },
    {
      "heading": "Therapeutics",
      "text": "Management in Belgium, Spain, Italy and the Netherlands. Care in the United Kingdom in the indication: \"LUMYKRAS is indicated as monotherapy for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell cancer (NSCLC), who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy\" AMM in the United States superposable to that in Europe: \"treatment of adult pa-tens with KRAS G12C mutated locally advanced or metastatic non-small cell cancer (NSCLC), as determined by an FDA approved to that in Europe: \"treatment of adult pa-tens with KRAS G12C mutated locally advanced or metastatic non-small cell cancer (NSCLC), as determined by an FDA approved to that in Europe:",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "General information on the disease or disease concerned",
      "text": "Bronchial cancer is the 2nd most common cancer in men and the 3rd most common in women among solid tumours (more than 46,000 new cases per year in 2018). The median age of diagnosis is 67 years with a majority of diagnoses (70 to 80%) carried out in locally advanced or metastatic stages. With 33 117 deaths estimated in 2018, bronchial cancer is also ranked first among cancer deaths in men and second among women. Non-small cell bronchial cancer (NCCB) accounts for almost 85% of all lung cancers.1 The prevalence of KRAS G12C mutation in CBNPC has been estimated at approximately 14%1.",
      "start_page": 5,
      "end_page": 6
    },
    {
      "heading": "Current support",
      "text": "Prior to the provision of LUMYKRAS (sotorasib), there was no specific treatment targeting the KRAS G12C mutation. The current therapeutic management is identical, whether or not patients have a KRAS mutation (including G12C).1 In the initial evaluation of LUMYKRAS (sotorasib), the Transparency Commission had considered that given the currently poorly established prognostic and predictive value of the KRAS G12C mutation, and the lack of comparative data of acceptable methodological quality, its place vis-à-vis therapeutic alternatives (chemotherapy and immunotherapy) could not be specified. The management of patients with advanced CBNPC, whose disease progressed after at least one previous treatment line (immunotherapy ± chemotherapy), is based on systemic treatment.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Medicated treatments",
      "text": "Table 1: List of drug treatments with MMA in the scope of the assessment NAME (INN) MMA indication Date of MRS ASMR Laboratory I-avis Generic Chemiotherapys of advanced or metastased CBNPC NA: NA: NA: cisplatin Accord, Teva: Via- tris 1 TB Notice of 15/06/2022 – LUMYKRAS – 19740_LUMYKRAS_PIC_INS_NoticeDef_CT19740.pdf CBNPC Generics NA: carboplatin Accord, Arrow, Hospira, Kabi, Teva: Viatris NAVELBINE CBNPC NA: (vinorelbine) Pierre Fabre and ge-nerics: Accord, Arrow, Sandoz TAXOL In combination with cisplatin, in NA: CBNPC for which po- (paclitaxel) therapeutically curative surgery and/or a radio- Bristol-Myers therapy n: (vinorelbine) not indicated, Aborz, Sandoz TAXOL In combination with cisplatin, in NA:",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "Immunotherapy",
      "text": "TECENTRIQ Monotherapy in local CBNPC- 30/05/ ment advanced or metastatic after (enter (atezolizumab) anterior chemotherapy Roche OPDIVO CBNPC epidermoid locally 03/02/ advanced or metastatic after (enter (nivolumab) anterior chemotherapy Bristol-Myers Squibb CBNPC non-epidermoid locally 11/01/ advanced or metastatic after (entered chemotherapy KEYTRUDA CBNPC locally advanced or metas- 03/03/ tatique, with PD-L1 ≥ 1%, and having (reeva (pembrolizumab) received at least one titre MSD chemotherapy) registered before the 1999 Order Governing MRS and ASMR GEMZAR (gemcitabine) and AVASTIN (bev line and more and recommended (AURA recommendation).",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "Coverage of medical need",
      "text": "Despite these treatments, the prognosis of advanced CBNPC is dark, with overall survival at 5 years ranging from 15% to 50% in patients eligible for targeted therapies or immunotherapy.1 The medical need is therefore currently partially covered by the alternatives available. However, there is still a medical need to have medicines that improve the overall survival and quality of life of these patients.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "Data available",
      "text": "The initial review of LUMYKRAS (sotorasib) was based primarily on a phase 1/2 basketball (CodeBreak 100) non-comparative study in 224 patients, 126 of whom had NSCLC, and whose main objective was to estimate the objective response rate, evaluated by an independent review committee. The main results of this study already examined in the opinion of 15/06/2022 will be recalled below. The laboratory had also submitted: - the data from an indirect comparison (CodeBreak 100 versus ESME cohort).",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "Synthesis of efficacy data",
      "text": "3.2.1 Reminders of clinical data previously reviewed by the Commission (Opinion of 15/06/2022): CodeBreak study 100 (non-comparative basketball study) \"A total of 126 patients with NSCLC were included. The median age was 64 years, with a similar proportion of men/women (50%) and patients in good general condition, with an ECOG stage of 0 (30%) or 1 (70%). Almost all patients had metastatic disease (96%) and a non-epidermoid tumour (99%). A total of 43% of patients had received only one year-long line, 35% two lines and 22% had received three previous lines.",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "Treatment received",
      "text": "Patients were randomized (allocation ratio 1:1) to receive: - Experimental group: sotorasib, 960 mg/day, oral route; - Control group: docetaxel, 75mg/m2 every 3 weeks, route IV (MMA posology); Randomization was stratified according to the following criteria: number of previous lines (1 vs. 2 vs. 3 and +), geographical origin (Asian versus non-Asian) and CNS (present vs. absent).",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Criteria for judgement",
      "text": "The primary endpoint was progression-free survival evaluated by an independent blind review committee. Progress-free survival was defined as the time between randomization and progression according to the RECIST criteria 1.1, or all-cause death. It should be noted that patients who started new cancer therapy prior to progression or death were censored at the date of last assessment prior to initiation. A sensitivity analysis was performed by considering these initiations as progression-free survival events. Note that in the event of death or progression immediately after missing at least two evaluations, patients were censored at the date of last assessment without progression or death. No sensitivity analysis was performed on this point. The following judgement criteria were monitored for the multiplicity of tests (alpha risk control).",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "Main amendments to the Protocol",
      "text": "In Amendment 3 to the Protocol of 15/02/21 (1st randomisation carried out on 04/06/2020), several modifications were made: - Reduction of the number of subjects from 650 to 330 patients; - Addition of an intermediate analysis of progression-free survival (160 events); - Crossover possible for patients in the docetaxel group, in case of progression according to the Inves-tigator and confirmed by the independent committee.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Study population",
      "text": "In this open-label study, 2 patients in the LUMYKRAS group (sotorasib) and 23 patients in the docetaxel group did not receive the treatment.",
      "start_page": 10,
      "end_page": 13
    },
    {
      "heading": "Quality of life",
      "text": "As no statistically significant differences were shown in terms of glo-bal survival, the hierarchical sequence was therefore stopped and the quality of life criteria were not tested. The quality of life of patients was analysed using the QLQ-C30 and QLQ-LC13 questionnaire. However, given the following limitations: - Open study, - Hierarchical analysis interrupted upstream, No formal conclusions can be drawn from the quality of life results, which will not be presented.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "Tolerance profile",
      "text": "3.3.1 Reminders of clinical data previously reviewed by the Commission (Opinion of 15/06/2022): CodeBreak 100 study (non-comparative basketball study) \"Tolerance data from the CodeBreak 100 study are derived from the data freeze of 15 March 2021, allowing the largest decline. The tolerance population was 126 patients, with a median treatment duration of 24 weeks (min-max: 1-77). Almost all patients reported an adverse event (AE) (99%). The proportion of AEs of grades ≥ 3 was 61%, that of serious AEs of 55%, that of AEs leading to discontinuation of therapy of 9%, and that of AEs leading to death of 16%. Events of special interest were reported in 39% of patients.",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "Data from the RMP",
      "text": "The risk summary of the LUMYKRAS RMP (sotorasib) (version 1.0 dated 15/11/2022) did not indicate any significant risk, potential risk or missing information.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Data from PBRER/PSUR",
      "text": "The Periodic Benefit-Risk Evaluation Report (PBRR)/Periodic Safety Update Report (PSUR) covering the period from 28/11/2021 to 27/05/2022 was provided in support of this re-evaluation. No signal was closed during this period.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "3.4.1 Cohort ATU",
      "text": "Reminders of the clinical data previously examined by the Commission (Opinion of 15/06/2022): Cohort ATU from 09/08/2021 to 29/10/2021 \"For a reminder, the wording of this cohort ATU was: \"Sotorasib is indicated as monotherapy in the treatment of adult patients with non-small cell bronchial cancer (NCBC) KRAS p.G12C metastatic mutation, pre-treated A total of 447 requests for access to treatment were made during this period, 7 of which were refused. Of the 440 accepted applications, 414 patients were considered treated (medianly provided by the laboratory). Of these, 403 patients were considered to have been exposed to so-torasib (11 patients who had never initiated treatment). The 414 patients considered as treated are described in the follow-up to this paragraph. Only 47 patients had a first documented follow-up visit.",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "3.4.3 Observational study IFCT-2102 Lung KG12Ci",
      "text": "This retrospective observational study was intended to include patients with stage IV NSCLC with KRAS G12C mutation, who received at least one dose of sotorasib under ATU. The main objective was to assess survival without progression known as \"real-life\" progression. A total of 106 patients who started treatment with sotorasib between 15/03/2021 and 15/04/2022 were included in this study. It should be noted that these patients have already been included in the cohort ATU description (paragraph 3.4.1). These 106 patients represent 10% of the 1,011 patients treated with ATU. Given the insufficient accuracy associated with this low number, and the possibility of bias in selection, these data are not likely to provide an unbiased estimate of efficacy and tolerance results in the ATU population. Therefore, these data do not include any data on the efficacy and tolerance of the NSCLC with the NSCLC.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Programme of study",
      "text": "Study Name Study Diagram Data Availability Study CodeBreak Phase II, multicentre, open-label dose comparison study May 2026 100 (NCT03600883) (240 mg vs 960 mg) in patients with KRAS G12C muta- tion who have received at least one prior systemic treatment",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Discussion",
      "text": "This opinion concerns the re-evaluation of LUMYKRAS (sotorasib), in its monotherapy indication in the treatment of adult patients with advanced non-small cell bronchial cancer (NCBC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line.",
      "start_page": 16,
      "end_page": 17
    },
    {
      "heading": "Conclusions of the Commission on Transparency",
      "text": "Considering all this information and after debate and vote, the Commission considers that within the scope of the assessment:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Place of the drug in the therapeutic strategy",
      "text": "LUMYKRAS (sotorasib) is a treatment option in the management of adult patients with advanced non-small cell bronchial cancer (NCBC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Clinically relevant comparators",
      "text": "In view of the current management (paragraph 2.2) and the place of the medicinal product in the therapeutic strategy (paragraph 5.1), the CCPs are the treatments mentioned in paragraph 2.2.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Medical Service Rendu",
      "text": "In the case of non-small cell lung cancer with KRAS G12C mutation, there are non-specific therapeutic alternatives to the KRAS G12C mutation, in a context where the prognostic and predictive value of this mutation is poorly defined and the lack of specific treatment (before the provision of LUMYKRAS (sotorasib).",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Improvement of the Medical Service Rendu",
      "text": "LUMYKRAS (sotorasib) demonstrated a statistically significant superiority in terms of progression-free survival and objective response rates evaluated by an independent review committee in an open-label randomised phase 3 study compared to docetaxel. However, this result is limited by: - the lack of clinical relevance of the absolute difference in median survival without progression, of about 1 month; - the open-label conduct of the study, which resulted in possible biases in assessment, particularly in terms of treatment decisions; - the uncertain reproducibility of the measure of progression-free survival in this study; - the absence of evidence of an effect on overall survival, in an advanced stage with an unfavourable prognosis; - the lack of clinical relevance of the objective response rate in this con − the absence of a formal conclusion that can be drawn from quality results −",
      "start_page": 18,
      "end_page": 19
    },
    {
      "heading": "Target population",
      "text": "The Commission considers that no data are likely to change the target estima achieved in the initial opinion.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Data request",
      "text": "Not applicable.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Other recommendations of the Commission",
      "text": "It is adapted to the conditions of prescription according to the indication, dosage and the LUMYKRAS 120 mg, 19 July 2023 All our publications are downloadable on text-based disease text; can only be used to improve the service of the treatment population. te lliu j tn a s e d tiro tu A e tu a H",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "table underheading <(ISP)>",
      "text": "Row 1 : - Lung cancer - Row 2 : - Adult - Row 3 : - Sectors : City and Hospital",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <(ISP)>",
      "text": "Row 1:的Advisory advice to maintain reimbursement \"as monotherapy in the treatment of pa---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <(ISP)>",
      "text": "Row 1: This specialty is not likely to have an additional impact on Row 2: Public health",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <The target population is estimated at about 1950 patients.>",
      "text": "Row 1 : - lack of evidence of an effect on overall survival, in the context of Row 2 : - lack of a formal conclusion that can be drawn from the quality results of Row 6 : - life; Row 7: - the safety profile of the sotorasib not appearing as more favourable than Row 8: - the docetaxel; Row 9: - the Commission considers that LUMYKRAS (sotorasib) does not bring d'améliora-- Row 10: - treatment of the medical service rendered (ASMR V) in relation to docetaxel. - Row 11: The target population is estimated to be about 1950 patients.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <Summary> (from previous page)",
      "text": "Row 1:------ -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page)",
      "text": "Row 1: DCI (ATC code) Row 2: Presentations Row 3: concerned*",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page)",
      "text": "Row 1: Lists) concerning- Row 2: born(s)",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page)",
      "text": "Row 1: Conditions and sta- Row 2: tuts",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 1)",
      "text": "Row 1 : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 2)",
      "text": "Row 1: Process Row 2: is Row 3: Row 4: Row 5: ode A Row 6: ntation Row 7: Born Row 8: Row 9: conc Row 10: Row 11: Row 12: andoire Row 13: ion c Row 14: r l ́év Row 15: Row 16: Row 17: Row 18: Row 19: ions Row 20: Row 21:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 3)",
      "text": "Row 1: edura Row 2: Row 3: Row 4: Row 5: ATC) Row 6: ns Row 7: s* Row 8: Row 9: cer- Row 10: Row 11: Row 12: e Row 13: conce Row 14: valua- Row 15: Row 16: Row 17: Row 18: Row 19: and sta Row 20: Row 21:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 4)",
      "text": "Row 1: al-al-Révaluation Row 2:--Row 3:--",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 4)",
      "text": "Row 1 : -sotorasib (L01XX73) - Row 2 : -LUMYKRAS 120 mg film-coated tablet - Row 3 : - 30 blisters PVC polyethylene PVDC aluminium 8: - Row 4 : - tablets (CIP 34009 302 419 3 6)",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 4)",
      "text": "Row 1: Row 2:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 4)",
      "text": "Row 2: er--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 4)",
      "text": "Row 1:的Initial date: 06/01/2022 (centralised procedure):::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <Summary> (from previous page, column 4)",
      "text": "Row 1: a- Row 2:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading < General about the disease or condition concerned>",
      "text": "Row 1:--- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "table underheading < General about the disease or condition concerned>",
      "text": "Row 1: Eva-Row 2: Pre-Row 3: Teeth",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "table underheading < General about the disease or condition concerned>",
      "text": "Row 1: Evaluation by Row 2: Commission",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "table underheading <的 Drug Treatments>",
      "text": "Row 1:的NOM (INN) & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication Date of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Indication of AMM & Ind.",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "table underheading <Immunotherapy>",
      "text": "Row 1: CBNPC-NA-NA-NA-NA-Row 2: In combination with cisplatin, in CBNPC for which po-tentially curative surgery and/or radiotherapy is not indicated, in combination with cisplatin, in CBNPC non-resectable, locally advanced or metastatic, in patients who have not received previous chemotherapy-rapy, in combination with cisplatin, in CBNPC non-resectable, locally advanced or metastatic, in patients who have not received previous chemotherapy, in combination with cisplatin, in combination with cisplatin, in combination with cisplatin, in CBNPC non-resectable, locally advanced or metastatic, in patients who have not received previous chemotherapy, 21/07/2004 (registration)",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <Immunotherapy>",
      "text": "Row 1: Locally advanced or metastatic CBNPC monotherapy after prior chemotherapy",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <Immunotherapy> (column 1)",
      "text": "Row 1: CBNPC Row 2: In combination with cisplatin, in CBNPC for which po-tentially curative surgery and/or radiotherapy is not indicated Row 3: In combination with cisplatin, in non-resectable CBNPC, locally advanced or metastatic, in patients who have not received anterior chemotherapy Row 4: Second-line CBNPC monotherapy, when histology is not predominantly epidermoid",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <Immunotherapy> (column 1)",
      "text": "Row 1: Monotherapy in local advanced or metastatic CBNPC after prior chemotherapy Row 2: locally advanced or metastatic epidermoid CBNPC after previous chemotherapy Row 3: locally advanced or metastatic non-squad CBNPC after previous chemotherapy",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <Discussion>",
      "text": "Row 1: Name of the study:Schedule of the study:Availability of the Row:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table underheading < Clinically relevant compares>",
      "text": "Row 1 : In view of all this information and after debate and vote, the Commission considers that within the scope of the evaluation:",
      "start_page": 17,
      "end_page": 17
    }
  ]
}